1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Teva’s Quartette data support US filing

 
• By Alexandra Shimmings

Teva Women’s Health has reported Phase III clinical data for its novel, dose-ascending extended-regimen oral contraceptive Quartette. The new product, which contains levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets, is currently under review at the US FDA after being accepted for review in August, and is the first dose-ascending oral contraceptive.

Teva Women’s Health has reported Phase III clinical data for its novel, dose-ascending extended-regimen oral contraceptive Quartette. The new product, which contains levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets, is currently under review at the US FDA after being accepted for review in August, and is the first dose-ascending oral contraceptive.

The results, presented this week at the American Society of Reproductive Medicine in San Diego, are from a 2,144-patient open-label...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Capsida Is Latest To Have Patient Fatality In Gene Therapy Trial

 
• By Alaric DeArment

The privately owned biotech said it would pause its Phase I/II study of CAP-002 in STXBP1-related disorders after the first patient in the study died.

Lundbeck CEO Looks To The Future With Sharper Commercial Focus

 
• By Kevin Grogan

Charl van Zyl tells Scrip that pipeline is the priority as the company discontinues commercial operations in 27 markets.

Dianthus Sees Best-In-Class Potential For Claseprubart In Crowded gMG Market

 
• By Mandy Jackson

Phase IIa data for Dianthus’ complement C1s inhibitor claseprubart in myasthenia gravis showed strong efficacy, less frequent dosing and no risk of infections relative to a growing list of competing drugs.

Rapport Moves Closer Toward Blockbuster Epilepsy Opportunity

 
• By Jessica Merrill

Phase IIa data testing RAP-219 could position it as best-in-class for focal onset seizures.

More from Therapy Areas

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.